Endoscopic sleeve gastroplasty (ESG) has emerged as a promising non-surgical alternative for weight loss and liver health improvement, significantly outperforming sham endoscopy in reducing body weight (–9.47% vs. –3.91%) and improving liver stiffness and steatosis. While ESG effectively enhanced NAFLD activity scores, its impact on fibrosis stages remained modest. Despite minor adverse events requiring brief hospitalization, ESG demonstrated a favorable safety profile. Positioned as a second-line treatment for metabolic dysfunction-associated steatohepatitis (MASH) and obesity, ESG shows potential, especially for patients unresponsive to lifestyle changes. Could this be the breakthrough for non-invasive management of complex metabolic conditions?
Trending
- Cancer risk comparable across advanced IBD therapies in claims analysis (GI & Hepatology News)
- Independent practice on the road to extinction: Why the next generation won’t own the stethoscope, let alone the building (Medical Economics)
- Fecal Burden on CT Weakly Correlates with Bowel Function in Adults and is Poorly Associated with Clinical Symptoms (Digestive Diseases and Sciences)
- Cook Medical issues medical device correction for Hemospray Endoscopic Hemostat (AGA)
- Medicare physician pay reform 2027: Patients First Act and 4 other bills explained (Physicians Practice)
- FDA Advisory Committee Votes In Favor of Approval of GRAIL’s Galleri® Multi-Cancer Early Detection Test (PR Newswire)
- Batteries that safely break down in the GI tract could improve ingestible devices (Medical Xpress)
- Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls (Gastroenterology)
